Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

BD, Babson expand access to fingertip blood testing

January 2025—BD and Babson Diagnostics announced an expansion of fingertip blood collection and testing technologies for use by U.S. health systems and other large provider networks in settings like urgent cares, doctors’ offices, and other ambulatory care settings. The blood testing process integrates BD’s MiniDraw capillary blood collection system with Babson’s BetterWay technologies to enable test results from as few as six drops of capillary blood collected from a patient’s finger. Samples can be collected and prepared by any trained health care worker, including those without prior phlebotomy experience.

Qiagen expands QIAcuity dPCR assay portfolio

December 2024—Qiagen announced the launch of 100 assays for its digital PCR platform QIAcuity, for use in the study of cancer, inherited genetic disorders, infectious disease surveillance, and others. The assays are available through the company’s GeneGlobe platform, which integrates predesigned assays with a database of more than 10,000 biological entities, including genes, miRNAs, and pathways.

Bio-Rad expands EQAS program

December 2024—Bio-Rad Laboratories has launched its External Quality Assurance Services specialty immunoassay program. The liquid, independent, and confidential external assessment program consolidates 13 complex and highly tested specialty immunoassay analytes, including procalcitonin, active vitamin B12, interleukin-6, and fructosamine, at normal and abnormal levels.

FDA clears Accelerate Arc system

December 2024—Accelerate Diagnostics announced FDA 510(k) clearance of the Accelerate Arc system and BC kit for use with Bruker’s MALDI Biotyper CA system and MBT-CA Sepsityper software extension. The Accelerate Arc system has a simple workflow that automates positive blood culture sample preparation for direct downstream microbial identification using Bruker’s MBT-CA system.

NeoGenomics launches AML Express

December 2024—NeoGenomics has launched its AML Express, a next-generation sequencing assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia. The panel includes an extensive list of genes selected for their clinical relevance in AML, covering DNA and RNA alterations, and is intended to be used in conjunction with clinical features and other laboratory results. The turnaround time is three to four days.

Pillar gets CPT code for FDA-approved OncoReveal CDx kit

December 2024—Pillar Biosciences has been granted a unique CPT proprietary laboratory analyses code 0523U from the American Medical Association for its FDA-approved OncoReveal CDx pan-cancer solid tumor in vitro diagnostic NGS kit.

Agilent releases Infinity III LC series

December 2024—Agilent Technologies announced the release of its next-generation Agilent Infinity­Lab LC series portfolio, which includes the 1290 Infinity III LC, 1260 Infinity III Prime LC, and 1260 Infinity III LC systems as well as biocompatible versions of each system.

Trial shows MeMed BV reduces use of unnecessary antibiotics

December 2024—MeMed announced the completion of its first randomized controlled trial to evaluate the MeMed BV test in the United States. Results from this trial demonstrate the clinical utility of the MeMed BV test in promoting appropriate antibiotic use, highlighting its potential to improve patient outcomes and optimize health care decision-making. “This achievement is a critical step toward making MeMed BV the standard for distinguishing bacterial from viral infections and advancing efforts to expand reimbursement coverage,” according to a company press statement.

Illumina expands TruSight Oncology portfolio

December 2024—Illumina announced it will release TruSight Oncology 500 v2, a new version of its flagship cancer research assay to enable comprehensive genomic profiling. The assay is under development; a worldwide release is planned for midyear 2025. TSO 500 v2 assesses hundreds of genes across all variant classes, as well as immuno-oncology biomarkers, in a single assay from one sample. Features of the new version include a faster turnaround time and reduced hands-on time; sensitive variant calling and improved coverage of difficult genomic regions; and new kit configurations with 50 percent less packaging, 70 percent fewer tubes, and improved usability.

Verichem offers reference materials for cholesterol assays

December 2024—Verichem Laboratories announced that it is now offering clinical reference materials intended for calibration and calibration verification procedures for total cholesterol, high-density lipoprotein, and low-density lipoprotein. The liquid-stable, ready-to-use Matrix Plus Total Cholesterol Reference kit, Matrix Plus Total Cholesterol Reference kit level F, and HDL Cholesterol Verifier kit feature universal compatibility with a variety of automated clinical chemistry systems. The serum-like formulation contains a blend of highly purified human source material and bovine biologicals in saline.

MARKETPLACE

TRENDING